{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:40:25Z","timestamp":1780630825066,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10620-018-5325-8","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T13:43:17Z","timestamp":1541166197000},"page":"493-502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents"],"prefix":"10.1007","volume":"64","author":[{"given":"David","family":"Gremse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Pilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Korczowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Claudia","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"5325_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/MPG.0b013e31819de871","volume":"49","author":"Y Vandenplas","year":"2009","unstructured":"Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49:498\u2013547.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5325_CR2","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/ajg.2009.129","volume":"104","author":"PM Sherman","year":"2009","unstructured":"Sherman PM, Hassall E, Fagundes-Neto U, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol. 2009;104:1278\u20131295. (quiz 1296).","journal-title":"Am J Gastroenterol"},{"key":"5325_CR3","doi-asserted-by":"publisher","first-page":"391631","DOI":"10.5402\/2012\/391631","volume":"2012","author":"SC Nwokediuko","year":"2012","unstructured":"Nwokediuko SC. Current trends in the management of gastroesophageal reflux disease: a review. ISRN Gastroenterol. 2012;2012:391631.","journal-title":"ISRN Gastroenterol"},{"key":"5325_CR4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s10620-006-9095-3","volume":"51","author":"SK Gupta","year":"2006","unstructured":"Gupta SK, Hassall E, Chiu YL, Amer F, Heyman MB. Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. Dig Dis Sci. 2006;51:858\u2013863. https:\/\/doi.org\/10.1007\/s10620-006-9095-3","journal-title":"Dig Dis Sci"},{"key":"5325_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/TCRM.S14425","volume":"6","author":"EV Guimaraes","year":"2010","unstructured":"Guimaraes EV, Guerra PV, Penna FJ. Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole. Ther Clin Risk Manag. 2010;6:531\u2013537.","journal-title":"Ther Clin Risk Manag"},{"key":"5325_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000076370","volume":"69","author":"JP Cezard","year":"2004","unstructured":"Cezard JP. Managing gastro-oesophageal reflux disease in children. Digestion. 2004;69:3\u20138.","journal-title":"Digestion"},{"key":"5325_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/archpedi.154.2.150","volume":"154","author":"SP Nelson","year":"2000","unstructured":"Nelson SP, Chen EH, Syniar GM, Christoffel KK, Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Arch Pediatr Adolesc Med. 2000;154:150\u2013154.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"5325_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/MPG.0b013e31815eeabe","volume":"47","author":"MA Gilger","year":"2008","unstructured":"Gilger MA, El-Serag HB, Gold BD, et al. Prevalence of endoscopic findings of erosive esophagitis in children: a population-based study. J Pediatr Gastroenterol Nutr. 2008;47:141\u2013146.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5325_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0022-3476(05)81561-6","volume":"123","author":"TS Gunasekaran","year":"1993","unstructured":"Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr. 1993;123:148\u2013154.","journal-title":"J Pediatr"},{"key":"5325_CR10","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1067\/mpd.2000.109607","volume":"137","author":"E Hassall","year":"2000","unstructured":"Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr. 2000;137:800\u2013807.","journal-title":"J Pediatr"},{"key":"5325_CR11","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.1097\/00005176-200211004-00003","volume":"35","author":"V Tolia","year":"2002","unstructured":"Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr. 2002;35:S308\u2013S318.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5325_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/01.mpg.0000214160.37574.d3","volume":"42","author":"V Tolia","year":"2006","unstructured":"Tolia V, Bishop PR, Tsou VM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40\u00a0mg pantoprazole in children (5\u201311\u00a0years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2006;42:384\u2013391.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5325_CR13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MPG.0b013e318176b2cb","volume":"46","author":"MA Gilger","year":"2008","unstructured":"Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2008;46:524\u2013533.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5325_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/01.MPG.0000155369.54464.41","volume":"40","author":"S Fiedorek","year":"2005","unstructured":"Fiedorek S, Tolia V, Gold BD, et al. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2005;40:319\u2013327.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5325_CR15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/MPG.0000000000000229","volume":"58","author":"I Haddad","year":"2014","unstructured":"Haddad I, Kierkus J, Tron E, et al. Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD. J Pediatr Gastroenterol Nutr. 2014;58:510\u2013517.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5325_CR16","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/j.1572-0241.2007.01152.x","volume":"102","author":"G Boccia","year":"2007","unstructured":"Boccia G, Manguso F, Miele E, Buonavolonta R, Staiano A. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? Am J Gastroenterol. 2007;102:1291\u20131297.","journal-title":"Am J Gastroenterol"},{"key":"5325_CR17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1365-2036.2011.04950.x","volume":"35","author":"E Hassall","year":"2012","unstructured":"Hassall E, Shepherd R, Koletzko S, Radke M, Henderson C, Lundborg P. Long-term maintenance treatment with omeprazole in children with healed erosive oesophagitis: a prospective study. Aliment Pharmacol Ther. 2012;35:368\u2013379.","journal-title":"Aliment Pharmacol Ther"},{"key":"5325_CR18","unstructured":"Takeda. Dexilant (dexlansoprazole) [package insert]. Deerfield: Takeda Pharmaceuticals America, Inc.; 2016."},{"key":"5325_CR19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1185\/03007990802693883","volume":"25","author":"M Vakily","year":"2009","unstructured":"Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009;25:627\u2013638.","journal-title":"Curr Med Res Opin"},{"key":"5325_CR20","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/TCRM.S66680","volume":"11","author":"JW Frye","year":"2015","unstructured":"Frye JW, Peura DA. Managing gastroesophageal reflux disease\u2014comparative efficacy and outcomes of dexlansoprazole MR. Ther Clin Risk Manag. 2015;11:1649\u20131656.","journal-title":"Ther Clin Risk Manag"},{"key":"5325_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/j.1365-2036.2009.03933.x","volume":"29","author":"P Sharma","year":"2009","unstructured":"Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation\u2014results from two randomized controlled studies. Aliment Pharmacol Ther. 2009;29:731\u2013741.","journal-title":"Aliment Pharmacol Ther"},{"key":"5325_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1365-2036.2009.03954.x","volume":"29","author":"DC Metz","year":"2009","unstructured":"Metz DC, Howden CW, Perez MC, Larsen L, O\u2019Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009;29:742\u2013754.","journal-title":"Aliment Pharmacol Ther"},{"key":"5325_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/MPG.0b013e31822a323a","volume":"54","author":"M Kukulka","year":"2012","unstructured":"Kukulka M, Wu J, Perez MC. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2012;54:41\u201347.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5325_CR24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.cgh.2007.02.033","volume":"5","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Richardson P, Pilgrim P, Gilger MA. Determinants of gastroesophageal reflux disease in adults with a history of childhood gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2007;5:696\u2013701.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5325_CR25","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20132194.","journal-title":"JAMA"},{"key":"5325_CR26","first-page":"45","volume":"47","author":"International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use","year":"2001","unstructured":"International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: guideline for Good Clinical Practice. J Postgrad Med. 2001;47:45\u201350.","journal-title":"J Postgrad Med"},{"key":"5325_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/gut.45.2.172","volume":"45","author":"LR Lundell","year":"1999","unstructured":"Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172\u2013180.","journal-title":"Gut"},{"key":"5325_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109\u2013117.","journal-title":"Drug Saf"},{"key":"5325_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2165\/00128072-200204100-00004","volume":"4","author":"BD Gold","year":"2002","unstructured":"Gold BD, Freston JW. Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment. Paediatr Drugs. 2002;4:673\u2013685.","journal-title":"Paediatr Drugs"},{"key":"5325_CR30","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308\u2013328. (quiz 329).","journal-title":"Am J Gastroenterol"},{"key":"5325_CR31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/j.1365-2036.2009.04137.x","volume":"30","author":"DA Peura","year":"2009","unstructured":"Peura DA, Metz DC, Dabholkar AH, Paris MM, Yu P, Atkinson SN. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther. 2009;30:1010\u20131021.","journal-title":"Aliment Pharmacol Ther"},{"key":"5325_CR32","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1586\/17474124.2015.1093932","volume":"9","author":"Y Vandenplas","year":"2015","unstructured":"Vandenplas Y, Hauser B. An updated review on gastro-esophageal reflux in pediatrics. Expert Rev Gastroenterol Hepatol. 2015;9:1511\u20131521.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"5325_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.0953-0673.2004.01832.x","volume":"19","author":"BD Gold","year":"2004","unstructured":"Gold BD. Review article: epidemiology and management of gastro-oesophageal reflux in children. Aliment Pharmacol Ther. 2004;19:22\u201327.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5325-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5325-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5325-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T14:54:50Z","timestamp":1605365690000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5325-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["5325"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5325-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]},"assertion":[{"value":"3 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Barbara Hunt and Maria Claudia Perez are employees of Takeda Development Center Americas, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. Betsy Pilmer was employed by Takeda Development Center Americas, Inc., at the time of this study. David Gremse and Benjamin D. Gold were consultants for Takeda Pharmaceuticals of North America. Bartosz Korczowski has no relevant conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available owing to protection of rights and safety of patients involved in the investigation (Title 21 CFR, Part 50).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The informed consent and assent forms described the planned and permitted uses, transfers, and disclosures of the subject\u2019s personal and personal health information for purposes of conducting the study, and further explained the nature of the study, its objectives, and potential risks and benefits. The informed consent and assent forms detailed the requirements of the participant and the fact that he or she was free to withdraw at any time without giving a reason and without prejudice to his or her further medical care. The date of informed consent\/assent was recorded on the forms. The informed consent and assent forms were approved by both the institutional review board\/independent ethics committees and the sponsor before use, and embodied the elements of informed consent and assent as described in the Declaration of Helsinki and the ICH Guidelines for GCP and were in accordance with all applicable laws and regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}